Active Ingredient History

NOW
  • Now
Vancomycin is a branched tricyclic glycosylated nonribosomal peptide produced by the fermentation of the Actinobacteria species Amycolatopsis orientalis (formerly Nocardia orientalis). Vancomycin became available for clinical use >50 years ago. It is often reserved as the "drug of last resort", used only after treatment with other antibiotics had failed. Vancomycin has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections: Listeria monocytogenes, Streptococcus pyogenes, Streptococcus pneumoniae (including penicillin-resistant strains), Streptococcus agalactiae, Actinomyces species, and Lactobacillus species. The combination of vancomycin and an aminoglycoside acts synergistically in vitro against many strains of Staphylococcus aureus, Streptococcus bovis, enterococci, and the viridans group streptococci. The bactericidal action of vancomycin results primarily from inhibition of cell-wall biosynthesis. Specifically, vancomycin prevents the incorporation of N-acetylmuramic acid (NAM)- and N-acetylglucosamine (NAG)-peptide subunits from being incorporated into the peptidoglycan matrix; which forms the major structural component of Gram-positive cell walls. The large hydrophilic molecule is able to form hydrogen bond interactions with the terminal D-alanyl-D-alanine moieties of the NAM/NAG-peptides. Normally this is a five-point interaction. This binding of vancomycin to the D-Ala-D-Ala prevents the incorporation of the NAM/NAG-peptide subunits into the peptidoglycan matrix. In addition, vancomycin alters bacterial-cell-membrane permeability and RNA synthesis. There is no cross-resistance between vancomycin and other antibiotics. Vancomycin is not active in vitro against gram-negative bacilli, mycobacteria, or fungi.   NCATS

  • SMILES: CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]6NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(=O)N)NC1=O)c7ccc(O)c(c7)c8c(O)cc(O)cc8[C@H](NC6=O)C(=O)O)c3O[C@@H]9O[C@H](CO)[C@@H](O)[C@H](O)[C@H]9O[C@H]%10C[C@](C)(N)[C@H](O)[C@H](C)O%10)c(Cl)c2
  • InChIKey: MYPYJXKWCTUITO-LYRMYLQWSA-N
  • Mol. Mass: 1449.27
  • ALogP: Missing data
  • ChEMBL Molecules:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral, Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.6150 - $171.8400

Australia

$3.9075 - $8.0558
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

(1s,2r,18r,22s,25r,28r,40s)-22-(2-amino-2-oxoethyl)-48-[2-o-(3-amino-2,3,6-trideoxy-3-methyl-alpha-l-lyxo-hexopyranosyl)-beta-d-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(n-methyl-d-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid | (2.2sp,3.5sa,2.6sp)-o(4.2),c(3.4):c(5.4),o(4.6):c(3.5),c(2.7)-tricyclo[n-methyl-d-leucyl-3-chloro-(r)-beta-hydroxy-d-tyrosyl-l-asparaginyl-d-2-(4-{[2-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-lyxo-hexopyranosyl)-beta-d-glucopyranosyl]oxy}phenyl)glycyl-d-2-(4-hydroxyphenyl)glycyl-3-chloro-(r)-beta-hydroxy-l-tyrosyl-l-2-(3,5-dihydroxyphenyl)glycine] | diatracin | vancocin | vancocine | vancocin hcl | vancocin hydrochloride | vancocin matrigel | vancoled | vancomicina | vancomycin | vancomycine | vancomycin hcl | vancomycin hydrochloride | vancomycinum | vancor | vanoled

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue